(±)-Lisofyllineanti-inflammatory agent |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
(±)-Lisofylline Dilution Calculator
calculate
(±)-Lisofylline Molarity Calculator
calculate
Cas No. | 6493-06-7 | SDF | Download SDF |
Synonyms | BL 194,CT-1501R,LSF | ||
Chemical Name | 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6-dione | ||
Canonical SMILES | CC(O)CCCCn1c(=O)c2n(C)cnc2n(C)c1=O | ||
Formula | C13H20N4O3 | M.Wt | 280.3 |
Solubility | ≤2mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | Storage | Store at -20°C |
Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
(±)-Lisofylline is an anti-inflammatory agent.
Anti-inflammatory refers to the property of a agent or treatment reducing inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids.
In vitro: (±)-Lisofylline is a potent anti-inflammatory agent in which only the (-) optical isomer is biologically active. (±)-Lisofylline was found to inhibit the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase. (±)-Lisofylline could also suppress the production of the proinflammatory cytokine IFN-γ, inhibit IL-12-mediated STAT-4 activation, as well as enhance glucose-stimulated β-cell insulin secretion [1].
In vivo: In a previous study, lisofylline was administered to female non-obese diabetic mice for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were also carried out in pancreatic sections. Results showed that lisofylline was able to suppress IFN-γ production, reduce the onset of insulitis and diabetes, and inhibit diabetes [1].
Clinical trial: A clinical trial has been conducted to determine whether the administration of lisofylline would decrease mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). However, this trial was stopped for futility at the first scheduled interim analysis. It was found that there was no significant difference between groups in the number of patients who had died at 28 days and there was no significant difference between the lisofylline and placebo groups in terms of ventilator-free days, infection-related deaths, resolution of organ failures, or development of serious infection [2].
References:[1] Yang, Z.D.,Chen, M.,Wu, R., et al. The anti-inflammatory compound lisofylline prevents type I diabetes in non-obese diabetic mice. Diabetologia 45, 1307-1314 (2002).[2] No authors listed. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002 Jan;30(1):1-6.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
可与MHCⅡ类分子结合的都是蛋白性抗原;多糖和脂类不易于MHCⅡ类分子连接,难以被TH细胞识别,因而多不是良好的免疫原;但有时可以诱导抗体性免疫应答。 抗原递呈(antigenpresentation)是辅佐细胞向辅助性T细胞展示抗原和MHCⅡ类分子的复合物,并使之与TCR结合的过程。这个过程是几乎所有淋巴细胞活化的必需步骤。抗原递呈之前,经处理后的抗原肽段已经连接在MHC分子顶端的槽中,这个复合物便是TCR的配体。TCR与配体结合的精确模式尚未清楚,一个合理的说法是TCR中α和β链的V段接触MHC分子的α螺旋(形成MHC分子顶端槽的肽段),使高可变的连接部(V-J及V-D-J)与抗原肽段相结合。这样保证了TCR识别抗原的特异性。
超抗原的递呈有独特的模式,它不需要胞内处理,可以直接与MHCⅡ类分子结合。超抗原不结合在MHCⅡ类分子的顶端槽中,而是结合在槽的外侧;与TCR结合时,不结合其α链,只结合β链的V节段。超抗原对TCR和MHCⅡ类分子的结合都非常牢固,象一支双向钩子将T细胞和辅佐细胞紧紧地连在一起,很容易使T细胞活化。另外,任何超抗原都只与含特殊β链V节段的TCR结合,这样的TCR约占外周T细胞总数的1%~10%,这一数字远远大于任何普通抗原所能识别的细胞数;所以某些产毒细胞感染时,容易发生急性期素休克综合征,就是超抗原刺激的结果。向左转|向右转
抗体(antibody)
看了百科以后依然不太明白,语言通俗一点最好。谢谢。